All News
Primer on Clinical Trials
In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?
Read Article
Predicting Cardiovascular Events in SLE
A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.
Read Article
Second Efforts in Treating RA Partial Responders
The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.
Read Article
Arthritis Clinical Trials Comparison Grid
https://t.co/BEvMKU1WEE https://t.co/2TpxMbWE7h
Links:
Dr. John Cush RheumNow ( View Tweet)
An incredible opportunity for a free Rheumatology Review course hosted by the Pakistan Rheumatology Society
-Event is virtual and registration is free
-Course starts tomorrow 10/16 at 1:30 PM Pakistan time (5:30 AM ET)
See below for details👇🏼👇🏼👇🏼 https://t.co/tHeFwRZHcG
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Sjogrens - Dx tips, myths & mistakes:
• SS not rare; affects 1 in 400
• 95% female, but SS is more severe in men
• African Americans have a severe systemic phenotype
• Asians report dryness Sxs
• Smoking & alcohol intake often avoided by SS pts
https://t.co/f4C0eYv9Ee https://t.co/OOEXfH6jQs
Links:
Dr. John Cush RheumNow ( View Tweet)
Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/jXxkEKnl8o https://t.co/mGPokRjkaP
Links:
Dr. John Cush RheumNow ( View Tweet)
Intravenous Immune Globulin in Dermatomyositis
Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this trial.
https://t.co/8QeEzX8Eqm https://t.co/hUVLUQJjN6
Links:
Dr. John Cush RheumNow ( View Tweet)
In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?
https://t.co/bnf9RyGJWV https://t.co/Md2TPN70hQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Salaries and Career Choices
A recent Doximity report shows how rheumatology salaries increase by years in practice. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience.
https://t.co/wxWQruIlu9 https://t.co/gUsIffoHn6
Links:
Dr. John Cush RheumNow ( View Tweet)
Popular Post: 2022 New ACR Guidance on Glucocorticoid-Induced Osteoporosis (GIOP)
The ACR has updated this guideline and includes recommendations on abaloparatide (PTHrP) and romosozumab, which are newly available since the ACR’s 2017 GIOP guideline.
https://t.co/1LEtUvjNUG https://t.co/IYaJzZmg39
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Announces 2022 Award Recipients
The ACR and the ARP proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation.
https://t.co/sB3IfvFBJD https://t.co/w8J4qFPvpF
Links:
Dr. John Cush RheumNow ( View Tweet)
Do you renal Bx your #SLE pts? Study of 277 SLE pts w/ US-guided percutaneous renal bx showed bleeding complications post biopsy to be 19.9% (minor 13%; major 7%); risk higher w/ thrombocytopenia (OR 7.12)low eGFR (OR 3.5) https://t.co/kYieyYTUuT https://t.co/ZGobCIcW6v
Links:
Dr. John Cush RheumNow ( View Tweet)
EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/EawqOGZEZe https://t.co/Bcp6rOReCR
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM: 70 yoWM w/ 3-wk temporal headaches, jaw pain with chewing, temporal artery tender and thickened, but NO vision Sxs. a 15, CRP 24 mg/L. and Doppler US showed “halo sign” . Temp art Bx confirmed the Dx of GCA https://t.co/mIUA8pMh2l https://t.co/o50MkidinC
Links:
Dr. John Cush RheumNow ( View Tweet)
J Rheum review shows 4,444 rheums in 2015 & 3,547 in 2020 recv some sort of pharma payments (There are ~5000 US Rheums). Pandemic drops affected travel, etc (98%), speaking (72%), meals (72%), but less consulting (23%) https://t.co/2UMqp4XDhJ https://t.co/dHtHUBO1Wk
Links:
Dr. John Cush RheumNow ( View Tweet)
Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit billed, $12.14 generated in downstream revenues (infusions, labs, surgery). Cognitive specialists are undervalued! https://t.co/YatkwrBCeQ https://t.co/OzSsxXKVhC
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2
Links:
Dr. John Cush RheumNow ( View Tweet)
Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/gBWhjhS8Nu https://t.co/5799lleK22
Links:
Dr. John Cush RheumNow ( View Tweet)
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/Rais8fKame https://t.co/F3B9W7u7VO
Links:
Dr. John Cush RheumNow ( View Tweet)